Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4R5Y

The complex structure of Braf V600E kinase domain with a novel Braf inhibitor

Summary for 4R5Y
Entry DOI10.2210/pdb4r5y/pdb
DescriptorSerine/threonine-protein kinase B-raf, 5-({(1R,1aS,6bR)-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl}oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one (2 entities in total)
Functional Keywordskinase, signal transduction, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (human)
Cellular locationNucleus : P15056
Total number of polymer chains2
Total formula weight67607.11
Authors
Feng, Y.,Peng, H.,Zhang, Y.,Liu, Y.,Wei, M. (deposition date: 2014-08-22, release date: 2016-02-24, Last modification date: 2024-02-28)
Primary citationTang, Z.,Yuan, X.,Du, R.,Cheung, S.H.,Zhang, G.,Wei, J.,Zhao, Y.,Feng, Y.,Peng, H.,Zhang, Y.,Du, Y.,Hu, X.,Gong, W.,Liu, Y.,Gao, Y.,Liu, Y.,Hao, R.,Li, S.,Wang, S.,Ji, J.,Zhang, L.,Li, S.,Sutton, D.,Wei, M.,Zhou, C.,Wang, L.,Luo, L.
BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Mol.Cancer Ther., 14:2187-2197, 2015
Cited by
PubMed Abstract: Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF(V600E) metastatic melanoma, their clinical efficacy in BRAF(V600E) colorectal cancer is far less impressive. Prior studies suggested that feedback activation of EGFR and MAPK signaling upon BRAF inhibition might contribute to the relative unresponsiveness of colorectal cancer to the first-generation BRAF inhibitors. Here, we report characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clinical investigation. In vitro, BGB-283 potently inhibits BRAF(V600E)-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAF(V600E) and EGFR mutation/amplification. In BRAF(V600E) colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAF(V600E) mutation. These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation.
PubMed: 26208524
DOI: 10.1158/1535-7163.MCT-15-0262
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.5 Å)
Structure validation

238582

PDB entries from 2025-07-09

PDB statisticsPDBj update infoContact PDBjnumon